Masashi Miyamoto, Kyowa Kirin CEO

Ky­owa Kirin pulls the plug on drug de­vel­op­ment for suc­ces­sor to Parkin­son's drug Nouri­anz

Three years af­ter Japan’s Ky­owa Kirin se­cured FDA ap­proval for an add-on ther­a­py to lev­odopa in Parkin­son’s, the com­pa­ny has scrapped its po­ten­tial suc­ces­sor. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.